Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn the highest tolerable dose of phenethyl
isothiocyanate (PEITC) that can be given to patients who have a lymphoproliferative disorder
that has been treated with fludarabine. The safety of PEITC will also be studied.